Biotech Values

[trade1]

drbio- I don't know what people expect MC-1 to provide, the reduced myocardial damage is a significant long term benefit. I doubt any cardioprotective drug will reduce the mortality rate within 30 days post CABG. If death occurs then it probably results from unusual stress during the post-operative recovery from infection, surgical technique, or a secondary disease process.

CABG's are performed to improve cardiac perfusion so you would not expect to see mortality from MI in the placebo or MC-1 groups. The heart should be in better condition after the surgery then pre-CABG so mortality should not be the primary clinical end-point.

All of us know this is a speculative investment, but the clinical results are impressive if looked on from an objective viewpoint.